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Abstract
The aim of this paper is to describe the development and use of a computer simulation model that can be used as a 
Decision Support System (DSS) to tackle the critical public health issues of the chronic diseases, HIV and HIV 
related Tuberculosis in the Russian Federation. The model was developed to enable health officials and decision 
makers to determine the impact of policies to control the chronic diseases spread in an area of Russia. This area, like 
many others in Russia and elsewhere, have recently witnessed an explosion of HIV infections and a worrying spread 
of the Multi Drug Resistant form of Tuberculosis (MDRTB).
The conclusions drawn is that a high population coverage with Highly Active Anti Retroviral Treatment (HAART)
(75% or higher), allied with high MDRTB cure rates, reduces cumulative deaths by 60%, with limited impact below 
this level. The contributions that this research offers are the development of a simulation model that can be applied 
as a DSS by public health officials and managers in order to inform policy making. By doing so, ways of best 
controlling the spread of HIV and MDRTB and reduce the mortality rate from these serious public health threats is 
provided. 
Keywords: HIV, Tuberculosis, HAART, Russia, System Dynamics, Decision Support Systems
INTRODUCTION
In the Information Systems (IS) area when implementing IS, a solitary emphasis to technology cannot provide a 
successful system (Sauer, 1993; Lyttinen and Hirschheim, 1987). Instead, several aspects including the processes, 
interactions and impacts of the various stakeholders of the system need to be considered (Lytinnen and Hirscheim, 
1987; Sauer, 1993). There are various types of organisations that are adopting IS, including, recently, healthcare 
providing establishments, such as hospitals, laboratories, primary care trusts and pharmacies. These establishments 
have also experienced failures during the implementation of IS and are searching for possible reasons. 
Researchers examining the healthcare context have found that IS implementation cannot be undertaken from a solely 
technological viewpoint, but issues related to human error, safety, risk and criticality need to be considered 
(Beynon-Davies and Lloyd-Williams, 1999). Similarly, Pouloudi (1998) and Currie and Brown (1997) established 
that when implementation does occur, a consideration of the stakeholders, i.e a human and organisational 
perspective, is required. The health sector functions and operates as an organisation where decision making occurs 
with the support and visions from the management level; therefore, the role of management is pertinent. Decision 
support systems (DSS) is the area of the information systems (IS) subject that is focused on supporting and 
improving managerial decision-making (Arnott and Pervan, 2005). DSS are interactive computer-based systems
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intended to assist decision makers utilize data and models in order to identify and solve problems and make 
decisions. The “system must aid a decision maker in solving unprogrammed, unstructured (or “semistructured”) 
problems...the system must possess an interactive query facility, with a query language that ...is ...easy to learn and 
use (Bonczek, Holsapple and Whinston, 1981; p. 19)”. DSS help managers/decision makers’ use and manipulate 
data; apply checklists and heuristics; and build and use mathematical models. In a DSS context, a model that can 
assist managers to form and implement informed decisions based on “what-if” analysis, is based on reality and is not 
an abstraction or simplification of reality is a simulation model (Power, 2002). In more defined terms, Power (2002) 
describes a simulation model as “a technique for conducting experiments with a computer model”. 
Currently the world’s health sector is gravely concerned and seeking ways of eliminating or reducing the numbers of 
deaths occurring from pandemics (Harper and Shahani, 2003). A pandemic that is causing the most anxiety is 
Human immunodeficiency virus (HIV). HIV is a retrovirus that can lead to Acquired Immuno Deficiency Syndrome
(AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic 
infections (Sowadsky, 1999; Coffin, et al, 1986). As of January 2006, the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and the World Health Organization (WHO) estimate that AIDS has killed more than 25 
million people since it was first recognized on December 1, 1981, making it one of the most destructive pandemics
in recorded history. It is estimated that about 0.6% of the world's population is infected with HIV (Joint United 
Nations Programme on HIV/AIDS, 2006). According to current estimates, HIV is set to infect 90 million people in 
Africa, resulting in a minimum estimate of 18 million orphans (Joint United Nations Programme on HIV/AIDS, 
2005).
In countries with a high prevalence of HIV, tuberculosis (TB) incidence is also high and increasing (WHO, 2003; 
Girardi, et al, 2000). Growing evidence suggests that HIV has become a key driver of tuberculosis infection and 
subsequent mortality in many parts of the world (Vajpayee, et al, 2004; Williams, Dye, 2003; Currie, et al, 2003). 
Indeed, each year, 200, 000 deaths from tuberculosis in sub-Saharan Africa are attributable to co-infection with HIV
(Williams and Dye, 2003). Indeed as found in previous research, anti retroviral treatment reduces both the mortality
and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries
(Palella, et al, 1998). 
Where tuberculosis is multidrug-resistant (MDRTB), the challenges are even greater (Coker, 2004). Strategies 
designed to control tuberculosis, such as the World Health Organization (WHO)’s Directly Observed Therapy-Short 
course (DOTS), will have to be adapted if they are to meet the additional challenge of coincident HIV effectively 
and there have been calls for greater integration of tuberculosis and HIV control programmes, with the addition of 
Highly Active Anti- Retroviral Treatment (HAART) to DOTS programs. This important shift in public health policy 
demands critical analysis. Yet, to date, there has been little research to quantify the likely impact of provision of 
HAART in transitional societies, challenged simultaneously with high rates of MDRTB and explosive outbreaks of 
HIV. 
In the last decade the Russian Federation and Former Soviet Union (FSU) countries have witnessed an explosion of 
communicable diseases infections. Official data from the Russian Federation health authorities suggest that 
incidences of communicable disease infections increased almost three folds from 34 per 100 000 to 92 per 100 000 
between 1991 and 2000 (Coker, et al, 2004). Similarly, the death rate from tuberculosis increased from 8 per 100 
000 in 1991 to 20 per 100 000 in 2001 (Floyd, et al, 2006). Regarding HIV, the situation is even worse as the 
Russian Federation and FSU countries top the list of countries in terms of the disease growth as one million among 
143 million Russians are believed to be infected with HIV (Coker et al 2004). More worrying is the emerging 
evidence that tuberculosis and HIV are conspiring to amplify their spread in the population (Atun, et al, 2007a; 
Atun, et al, 2007b).
Although the social and economic conditions can be blamed partially for this situation, the health system structure in 
Russia bears a great degree of responsibility in this situation. The system is chronically under-funded, heavily 
dependent on outdated infrastructure and processes, and vertical, that is focusing on a single disease and ignoring its 
interactions with others (Coker et al 2004). Legal, organizational, and financial contexts have created a situation 
such that HIV control policies are ineffective (Atun, et al, 2005). Harm Reduction (HR) programmes designed to 
help those at risk of HIV infection cover a limited fraction of the population (Tkatchenko-Schmidt, et al, 2008). 
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1More disturbing is the fact that HR policies are not recognised within the Russian HIV control strategies and 70% 
of resources are provided by international donors (Rhodes, et al, 2004).
As the scale of the communicable disease infections problem requires urgent and effective action in order to 
implement effectively and efficiently currently available clinical interventions, this research aimed to describe the 
development and use of a computer simulation model that can be used as a Decision Support System (DSS) to
inform the process of designing policies to tackle the critical public health issues of HIV and HIV related 
Tuberculosis in the Russian Federation.
By undertaking research such as this the benefits to the infectious diseases research area are immense. Having such a 
simulation model can allow the potential impact of several policy scenarios on deaths from tuberculosis to be 
considered; thereby informing the policy-making process. This means that policy makers will be able to determine 
using tangible evidence (simulation model) the impacts of their efforts (policies). For practitioners and industry, 
risks can be reduced since there will be a diagrammatic and visual model that is not an abstraction or simplification 
of reality, but can calculate the impacts (in terms of resources, labour, money and time). For academics, there will be 
more research (DSS and simulation) to consider in terms of HIV and HIV related tuberculosis. Further benefits for 
industry lie in that there are many pharmaceutical companies seeking to determine the impacts of their medical 
treatments. By undertaking research such as this, the risk factor can be reduced and costs (monetary and time) can be 
reduced. 
To acquaint the reader to this paper the structure of this paper is described. Following this section a background of 
Russia and the theoretical basis of DSS is provided. Following this, the research approach that was applied to obtain 
the findings is provided. Thereafter, the findings and analysis of this research is proffered. This is followed by a 
discussion of the research findings and finally, a conclusion of this paper is provided. 
BACKGROUND
Russia, HIV and HIV related Tuberculosis
Whilst concern over HIV sufferers in Africa grows, there are other parts of the world where the disease has made a 
huge impact and increased the numbers of sufferers. In Europe, Russia has the largest numbers of HIV sufferers’ 
population. At the end of 2007 Russia had 1.6 million HIV sufferers and accounted for two thirds of the HIV cases 
in Eastern Europe and Central Asia. There are 12 regions in Russia, including the major cities of Saint Petersburg 
and Moscow, where HIV prevalence rates are said to be ‘above high’, and a further 11 with high prevalence rates
(UNAIDS, 2004a). The deputy prime minister of Russia, Alexander Zhukov, has stated that ‘the growth of AIDS 
has gone beyond a medical problem, and has become an issue of strategic, social and economic security of the 
country’ (Klomegah, 2005a).
European countries pledged to ensure universal access to treatment and care by 2005 across the whole of Europe and 
Central Asia and aimed to make sure 80% of ‘high-risk’ people had access to prevention services by 2010. 
However, at the end of 2004 only a small percentage of ‘high-risk’ people were being reached by prevention 
programmes (UNAIDS, 2004b). Cesar Chelala, an international public health consultant noted that in April 2005 
Russian prevention efforts were almost nonexistent. On a positive note, in Central Asia a prevention project has 
been launched which will train medical workers and other people, and it is thought this and other treatment and 
prevention programmes could make a real difference in the area (Adams, 2005). 
To assist drug users from drug related harm, such as becoming infected with HIV, Harm reduction programmes are 
being developed. Whilst these programmes do not deny the benefits of giving up the drugs altogether, they recognise 









programme is the introduction of needle exchanges where injecting drug users can exchange dirty needles for clean 
ones. If a clean supply of needles is available to injecting drug users then they will be less likely to share needles, 
therefore reducing the risk of contracting HIV. For example, in a major study of 81 cities around the world on HIV 
infection rates amongst injecting drug users IDUs, it was found that in 52 cities without needle exchanges HIV 
infection increased year on year, whilst in those cities with needle exchanges HIV infections decreased year on year
(Dailey, 2002). 
In addition to needle exchanges, harm reduction programmes also determine ways of encouraging IDUs to stop 
using drugs. One key way of doing this is by providing them with alternatives such as methadone. These alternatives 
are administered at clinics, and once inside, visitors can be offered further tests and treatment. Psychological 
assistance can be provided also, making the visitor feel valued and enriching their life. 
Unfortunately, harm reduction services in Russia, Eastern Europe and Central Asia are not nearly adequate to meet 
demand. In general authorities prefer to criminalise drug users rather than help them to give up drugs or avoid 
infection. In some countries - including Russia - substitution treatment with methadone is illegal (International 
Family Health, 2003). 
Although Russian law guarantees people treatment, only around 16,000 (11%) of the 140,000 needing treatment 
were receiving it at the end of 2006. Coverage is much lower than in many poor African countries such as Zambia 
(35%), Malawi (43%) and Uganda (41%), which have much more severe epidemics (WHO, 2007). One reason for 
the low treatment figures is that medicines are very expensive. This is however becoming less of a problem, 
particularly in Russia. In early 2005 the Russian minister of health, Mikhail Zurabov, announced that agreements 
had been made with pharmaceutical companies which would reduce the amount an AIDS patient had to spend on 
medicines from US$10,000 a year to around US$3,000 (Klomegah, 2005b). The Russian government announced in 
late 2005 that it would make AIDS a priority and pledged to spend at least 20 times more on treatment and 
prevention in 2006 than it spent in 2005 (Bloomberg, 2005). A year later it was announced that spending would be 
doubled to US$289 million in 2007 (Nowak, 2006). This increase has been aided by the Global Fund to Fight AIDS, 
TB and Malaria, which has pledged US$209 million over five years for treatment programmes (Sargent, 2006). Yet 
although it is hoped that the extra money will enable a rapid expansion of treatment access in Russia, there are other 
issues to address besides funding, including pervasive discrimination and segregation. People living with HIV in 
Russia must attend special clinics for all of their medical needs. These clinics are isolated from the rest of the health 
care system and anyone who visits them risks being stigmatised. Moreover, the lack of integration means that 
doctors and nurses in non-specialist clinics have very little knowledge of HIV (Brown, 2006). 
Theoretical Basis
DSS is a significant sub-field of IS scholarship with a research focus on development, technology, process and 
outcome studies (Arnott and Pervan, 2005). Much of the early work on DSS was highly experimental, even radical 
(Alter, 1980; Keen and Gambino, 1983). At the time, the aim of early DSS developers was to create an environment 
in which the human decision maker and the IT-based system worked together in an interactive fashion to solve 
problems; the human dealing with the complex unstructured parts of the problem, the information system providing 
assistance by automating the structured elements of the decision situation. The emphasis of this process was not to 
provide the user with a polished application program that efficiently solved the target problem. In fact, the problems 
addressed are by definition impossible, or inappropriate, for an IT-based system to solve completely. Rather, the 
purpose of the development of a DSS was an attempt to improve the effectiveness of the decision maker.
The health care area has recognized the importance of DSS in decision making and is using it to conduct research in 
various contexts. Designed for, and in conjunction with, different HIV and AIDS clinics in Mumbai, India, a patient 
progress operational model of patient care has been developed to predict future patient numbers and associated 
health care costs. The suitably detailed simulation model has been designed with flexibility, ease-of-use and lack of 
data in mind for developing country conditions. The model has been shown to yield a useful tool to aid decision-
making by clinicians and managers, thus helping in the provision of effective and efficient care to the many HIV and 
AIDS patients throughout Mumbai and potentially the rest of India (Harper and Shahani, 2003).

In the UK DSS is being used to develop a Clinical DSS (CDSS) for the pediatricians’ (Ramnarayan and Britto, 
2002).Using the case study of a free, web based CDSS titled ISABEL the researchers illustrate how using 
proprietary pattern recognition software called Autonomy (www.autonomy.com) to search standard paediatric 
textbooks, a differential diagnostic tool produces a list of up to 15 diagnoses to consider for any given set of clinical 
features. Further decision support is provided by text, annotated images, and practice guidelines specific to each 
diagnosis.
Breast cancer research has also attempted to utilize DSS. The study looked at the value of decision support in the 
initial assessment (‘Triple Assessment’) of women referred to specialist breast clinics. A collaborating breast 
surgeon used PROforma to formalize national guidelines for genetic risk assessment and for decisions about
imaging (mammography and ultrasound), biopsy and management (Fox, Patkar, and Johnson, 2006). 
Therefore, it can be learnt that DSS is being considered useful for decision making in the health care sector and not 
only for design, development and implementation issues in IS research.  
RESEARCH APPROACH AND THE DECISION SUPPORT SYTEM
A System Dynamics (SD) simulation model (Sterman, 2000) was developed to represent the transmission dynamics 
of tuberculosis and HIV. SD methodology was chosen because the transmission of infectious diseases is complex, 
involving many interacting variables, interconnected feedback loops, and non-linear cause-effect relationships. 
Given the dynamic complexity of these systems, their behavior is generally difficult to predict. Formal system-based 
modeling approaches, such as SD, can represent these systems, simulate their behavior, and predict the impact of 
health system interventions to support policy-makers in determining the most appropriate actions to improve health 
outcomes (Dangerfield, Fang, and Roberts, 2001)
The SD model was used to assess the impact of implementing  internationally recommended policies on the spread 
of these two diseases including the resulting deaths from the diseases over the next decade in a region of the Russian 
Federation. The simulation model was designed to be friendly and easy to use to allow public health decision makers 
and medical staff, with limited knowledge in computing, to easily use it in order to simulate scenarios and get their
results. As such the simulation model acted as a DSS to help decision makers in different parts of the public health 
system conduct experiments, analyze results, learn about the complexity of the two diseases, and come to a shared 
understanding of the rationale to implement the policies derived from the simulation model (See Figure 1 for a high 
level structure of the DSS).
Model Development
The first phase in the model development aimed to understand the epidemiology of TB and HIV including the 
processes of infection and transmission of these diseases in the population.  This phase was important as it allowed 
the research team, local clinicians and policy makers from the Ministry of Health in Samara to jointly develop a 
better understanding of the factors that influence the spread of TB as well as the mechanisms of its transmission in 
the population. This phase also enabled the local counterparts to understand the complexity of the TB control system 
that they would be operating, and to appreciate the importance of holistic and systemic approaches associated with 
understanding and applying such a system.
The research team obtained ethical approval from the local research ethics committee, and permission from the 
regional Ministry of Health to access epidemiological, health services and financing data. A multidisciplinary design 
team, comprising local and international researchers involved in the project, was established to include clinicians, 
health system and public health specialists and microbiologists with knowledge and experience of modeling TB and 
HIV. The members of the design team worked closely with policy makers; thereby being aware of the local, national 
and international issues relevant to policy makers. Through an iterative process of discussions and triangulation, 
drawing on the expertise of the group and published literature, model components and details were developed, 
parameters identified and the model populated. Local practitioners, experts and policy makers were also involved in 
discussions in model development, to test assumptions, check model validity and in scenario planning. This led to 
the construction of the transmission dynamics model for TB and HIV which is described below.

In order to verify that the relevant and correct data and information was being obtained, several visits were made by 
the research team to Samara. There was an occurrence of interviews with key informants and visits to provider units 
where TB services were delivered. The structure of TB and HIV transmission dynamics were determined drawing 
on the published literature and the knowledge-base of team members, complemented by interviews with clinicians 
and public health specialists in Samara. The literature review and discussions among the research team members led 
to an initial, high-level, simplified map of the disease epidemiology.  Following this, around 20 interviews were 
conducted in Samara with a broad set of stakeholders, comprising clinicians, nurses, managers from healthcare 
provider facilities, and policymakers from the Ministry of Health.  The map was presented to interviewees and 
iteratively refined following comments.  The map was ‘frozen’ once all interviewees agreed on its structure. 
The second phase of the development focused on the building of the computer simulation model. This phase was 
divided into two stages. First, we constructed a tuberculosis transmission dynamics model –– including disease, 
detection and treatment of both DSTB and MDRTB. Second, we extended the model by adding HIV/AIDS, 
including acquisition and spread of HIV, development of AIDS and the effects of treatment with HAART for 
individuals with late-stage HIV or AIDS.
Model of DSTB transmission
The natural history of tuberculosis transmission is represented by a stock and flow structure in which individuals
move from the state of ‘susceptible individuals’ to the state of ‘latently infected individuals’. From the latently 
infected state, some individuals progress to the ‘DSTB disease’ state rapidly, whereas others progress slowly
(Blower, et al, 1996). Without therapeutic interventions, individuals with disease may die, develop persistent disease 
or ‘self-cure’ (Vynnycky and Fine, 1999)
The model incorporates a therapeutic intervention for individuals who have progressed to the ‘DSTB disease’ state. 
These individuals, when detected, enter a drug treatment phase for the first time. They may die, be cured or develop 
persistent disease. Those with persistent disease may remain in that state, die or return to treatment at a later stage, a 
state from which, again, they may remain, die or be cured.
Model of MDRTB transmission
From the interview findings it was revealed that two processes drive the spread of MDRTB. First, individuals with 
DSTB entering treatment for the first time may develop MDRTB – a process known as secondary or acquired
infection. Second, susceptible individuals who come in contact with individuals with acquired MDRTB may
develop tuberculosis with a multidrug-resistant strain of Mycobacterium tuberculosis, a process known as primary 
MDRTB (Tahaoglou, et al, 2001). These individuals progress to the ‘MDRTB disease’ state rapidly or slowly, in a 
similar fashion to DSTB. Individuals with MDRTB enter a treatment phase from which they may progress to three 
states: death, cure or persistent MDRTB.
Model of HIV transmission
The HIV transmission sub-system model assumes individuals will be in one of three states: (i) HIV seronegative, (ii)
HIV seropositive or (iii) AIDS. Any individual represented in any of the states described in the tuberculosis model 
will also be represented in one of the three states described in the HIV transmission model. Figure 2 presents the 
HIV transmission process for one specific tuberculosis state, ‘latently infected DSTB’. 
Given that in the Russian Federation a very high proportion of HIV-seropositive individuals acquired HIV through 
intravenous drug use and a small proportion through secondary sexual spread, the model restricts transmission to the 
intravenous drug use route (Rhodes, et al, 2002). The transmission risk of moving from HIV seronegative to HIV-
seropositive state depends on: (i) the average number of injections per unit time, (ii) the probability that the injection 
equipment is contaminated with HIV, (iii) the probability of HIV transmission and (iv) the prevalence of intravenous 
drug users (IDUs) in the overall adult population (Grassly, et al, 2002). For the purposes of our model, the 
proportion of the population who are IDUs is assumed to remain constant.

Individuals who become HIV seropositive are assumed to progress over a period of 10 years to develop AIDS. Due 
to the breakdown in the immune system that results, co-infection with DSTB or MDRTB means that these
individuals will progress faster to the corresponding disease states than individuals without AIDS. If an individual 
with AIDS is not treated with HAART, it is assumed that they will die within two years. However, individuals 
treated with HAART may live for a period of 10 years after reaching the AIDS disease state. Furthermore, if an 
individual co-infected with AIDS and tuberculosis is treated with HAART, their disease progression is similar to
that of an individual without HIV/AIDS.
PARAMETER ESTIMATION AND MODEL VALIDATION
The parameters in the model have been drawn from published estimates in archival medical reports and, where these 
are unavailable, explicit assumptions deemed to be close to real life situations (confirmed by the interviews and 
discussions) were made. We identified studies through a systematic Medline search and obtained data from locally 
collected routine statistics. Tables showing tuberculosis transmission parameters corresponding to the HIV-
seronegative, HIV-seropositive and AIDS states are not shown but are available from the authors on request.
To validate the model before its use for scenario analysis, trends were compared against available data regarding 
cumulative tuberculosis deaths in Samara Oblast from 1997 to 2002. The model replicated, with a high level of 
accuracy, the real world dynamics of the most important variables such as tuberculosis prevalence and cumulative 
deaths (Atun et al 2005)
INTERVENTIONS AND SCENARIOS
Following the interviews with the practitioners and other related personnel scenarios were created. The scenarios 
tested in the model included policies related to the effectiveness of MDRTB treatment and the level of population 
coverage with HAART treatment. With respect to MDRTB, two effectiveness levels are selected: (i) 5% cure rate 
and (ii) 80% cure rate. The first level reflects documented outcomes of DOTS programs implemented in Russia
(Centers for Disease Control and Prevention, 1999). The second level represents what can be potentially achieved 
with a well-resourced and well organized MDRTB control program with access to second-line drugs (Mitnick, et al,
2003). With respect to HAART coverage, five possible scenarios ranging from no population coverage (0%) to full 
coverage of all individuals infected with HIV who are likely to benefit (100%) with 25% increments, including 25%,
50% and 75% coverage. The impact of these scenarios on the cumulative deaths from tuberculosis, MDRTB and 
deaths associated with AIDS were analyzed. Under all the scenarios, it was assumed that there was a case detection 
rate of 70% for cases of infectious tuberculosis and 85% treatment success rate for cases of drug susceptible 
tuberculosis (DSTB), in line with targets set by the World Health Organization (WHO).
Scenario analysis parameters
Scenario analysis parameters include MDRTB cure rate and HAART population coverage. MDRTB cure rate is 
assigned to two levels: 5% and 80%. HAART population coverage varies from 0% (no coverage) to 100% (full 
coverage) with increments of 25%. The time frame for the simulation model is 10 years and is assumed to start at 
the beginning of 2003 and finish at the end of 2012. The initial values in the simulation correspond to the number of 
adults in each of the tuberculosis and HIV states represented in the model at the beginning of year 2003. These 
values are presented in Table 1.
Model outputs
The model predicts the following outcomes: (i) cumulative deaths from tuberculosis that includes deaths from all 
forms of tuberculosis and deaths from HIV-associated tuberculosis; (ii) cumulative deaths from HIV-associated 
tuberculosis and (iii) cumulative deaths from HIV associated MDRTB.
FINDINGS
Samara Region has a total population of 3.3 million people, of whom 1.6 million are adults. In January 2003, the 
estimated prevalent number of individuals with tuberculosis was 2690, of whom 40% had MDRTB (Table 1). The 

region has experienced an explosive epidemic of HIV, and by January 2003 there were an estimated 17,000 
prevalent cases (Table 1).
The cumulative deaths from tuberculosis, with two levels of MDRTB cure rate of 5% and 80% and the five levels of
HAART coverage (from 0% to 100%), are presented in Figure 3. The results indicate that in the 10-year period of
simulation, in the absence of HAART coverage, the cumulative number of tuberculosis deaths will be 6650 with an 
MDRTB cure rate of 5%, but will decline to 4888 if MDRTB cure rates reach 80%. With an increase in HAART
coverage, the cumulative number of tuberculosis deaths initially declines at a slow rate as long as coverage rates are
below 50%. Between 50% and 75% the rate of decline increases, but with coverage rates of 75% and beyond, the 
rate of decline increases significantly. Hence, the cumulative number of deaths from tuberculosis at 5% and 80% 
MDRTB cure rates decline: (i) with 25% HAART coverage by 3% to 6473 at 5% MDRTB cure rate and 3% to 4721 
at 80% MDRTB cure rate, respectively; (ii) with 50% HAART coverage by 7% to 6162 and 9% to 4428; (iii) with
75% HAART coverage by 17% to 5505 and 22% to 3808 and (iv) at 100% HAART coverage declines substantially 
by 46% to 3595 and 60% to 1993, respectively (Figure 3).
Cumulative deaths from HIV-associated tuberculosis with no HAART coverage reach 3686 and 3473 when
MDRTB cure rates are, respectively, 5% and 80% (Figure 4). At 5% and 80% MDRTB cure rates, cumulative HIV-
associated MDRTB deaths decline in a non-linear manner: (i) at 50% diminish by 68% to 80 and by 80% to eight 
with 5% and 80% MDRTB cure rates, respectively (Figure 5).
DISCUSSION
For this research a setting where there is currently a high prevalence rate of MDRTB and an immature, contained 
epidemic of HIV in IDUs, the epidemic of MDRTB was used. If left unchallenged with effective MDRTB treatment 
but in particular high HAART coverage, this may result in a substantial number of deaths from tuberculosis.
Many deaths from tuberculosis, HIV-associated tuberculosis and HIV-associated MDRTB can be averted with 
effective tuberculosis and MDRTB control strategies that achieve high MDRTB cure rate and coverage of HIV 
infected people with HAART. However, the rate of decline in the cumulative number of deaths is not linearly 
proportional to the rate of increase in HAART coverage. Instead, we observed a slow change in the rate of decline 
for cumulative deaths from tuberculosis, HIV-associated tuberculosis and HIV-associated MDRTB up to 50% 
HAART coverage rates. The rate of decline increases between 50% and 75% HAART coverage and more 
substantially between 75% and 100% coverage. This relationship holds good for both 5% and 80% MDRTB cure 
rates.
For research, these findings have important policy implications. At low HAART coverage rates, the impact on 
cumulative deaths is minimal, but the impact increases substantially at coverage rates above 50% and particularly 
above 75%.
Current policy recommendations for HAART coverage focus on scaling up but does not explicitly identify an 
optimal coverage target (World Health Organization, 2005). It is demonstrated that in the epidemiological setting 
described above, scaling up HAART coverage to levels up to 50% is likely to achieve minimal impact, with an 
appreciable impact on mortality only becoming apparent at 50–75% coverage and becoming substantial only at 75% 
coverage level and beyond.
HAART coverage by 13% to 3204 and 14% to 3014; (ii) at 75% coverage by 31% to 2552 and 32% to 2396 and (iii) 
beyond 75% coverage, the number of deaths declines substantially so that when 100% HAART coverage is 
achieved, HIV-associated tuberculosis deaths fall by 83% to 657 and by 84% to 585, respectively (Figure 4). The 
acceleration in the decline in death rates beyond 75% is much faster for HIV-associated tuberculosis deaths than for 
tuberculosis only deaths.
In the absence of any HAART coverage, the cumulative number of deaths from HIV-associated MDRTB is 250 at 
5% and 42 at 80% MDRTB cure rates, respectively. The cumulative number of HIV-associated MDRTB deaths 
declines substantially with HAART coverage of 75% and beyond, and at 100% HAART the number of deaths 
reaches 80 at 5% and 8 at 80% MDRTB cure rates.
 
The non-linear relationship between increased HAART coverage and decline in cumulative death rates can be 
explained by the complex interactions at play between different elements of the tuberculosis and HIV transmission 
systems. Systems with complex relationships, which include feedback loops, behave in a non-linear manner and 
may respond in counter-intuitive ways to interventions, which are designed to influence system elements (Sterman, 
1989). This may result in ‘policy resistance’. One way to reduce this policy resistance is to adopt ‘systems thinking’, 
which requires a detailed analysis of these system elements and the ways they interact (Senge, 1990)
CONCLUSIONS
In terms of the aim stated at the outset of this paper it can be learnt that development and implementation of a 
simulation model such as the one suggested in this paper is a complex and iterative issue, but highly regarded as 
essential. HIV and HIV related pandemics are occurring around the globe in incremental numbers and is a grave 
concern that needs to be examined and recued or eliminated. However, although this research has important 
implications, it is still in development stages and limited in a number of ways. 
First, the model assumes a static age structure such that younger cohorts of individuals, who may be at risk of 
tuberculosis and HIV, are not considered within the model. It is assumed that as cohorts age, they are likely to 
influence the transmission dynamics of these two infections. The extent of the HIV epidemic may be underestimated 
in the model because the population at risk of HIV, which is the IDU population, remains static. In reality, it is likely 
that new young people will enter this population, swelling its ranks. Research is continuing to include age structure 
and wider transmission of HIV in this model. Similarly, the model does not include the consequences of population 
migration to and from the region. The Samara region, however, has a relatively stable population and was chosen as 
the population to model, in part, for this reason. Any changes in this pattern of population movement could impact 
upon predictions. It is assumed that the HIV spread will be contained within the IDU population, which is a further
limitation. In future it is likely that there will be significant sexual spread that will lead to leakage outside this
population. These factors are expected to lead to an underestimation of the likely epidemic of HIV in the region and, 
consequently, of the impact with tuberculosis dynamics.
In practice, both HIV and tuberculosis tend to cluster in certain sub-populations, and micro-epidemics may occur,
for example, through institutional spread within prison settings or in tuberculosis hospitals. Our model does not
predict such scenarios and, consequently, may again underestimate the likely impact of such enhanced transmission
dynamics. The model does not take into account possible policy changes. In our model, for example, the number of 
contacts per unit time between tuberculosis-susceptible and tuberculosis- infected individuals is assumed to be 
constant, and the model does not account for quarantine or isolation policies or changes in, for example, contact 
rates due to reactions from susceptible individuals to perceived risks in infected groups. The same assumptions hold 
good regarding the rate of acquiring HIV. The rate of movement from the HIV-seronegative state to the HIV-
seropositive state isassumed to be constant regardless of the individual’s tuberculosis state, a factor that might be 
influenced, for example, by institutional care practices and the patient’s behaviour within institutions. 
Notwithstanding these limitations, we believe that the findings are sufficiently robust to inform policy.
However, despite these limitations this research has important implications and if developed further in the future 
offers pertinent results and implications. We foresee the future as being one where the research will be focused upon 
considering some of the variables that we could not consider due to the setting or the sample population that utilized. 
Further, to ensure that the practitioners and other individuals requiring the application will be able to do and offer 
advice and support when required the foreseen strategy is being viewed as one where implementation will occur by 
utilizing the simulation model as a web based model. This way accessibility will be offered 24/7 and from any 
location anywhere around the globe. This way, practitioners can access the model when required and offer advice to 
patients when advice and support are required. 
For governments, and funding agencies such as the WHO, the Word Bank and the Global Fund our research has 
important implications as they are investing significant funds to control the tuberculosis, MDRTB and HIV 
epidemics in post Soviet countries. The investment in HAART should be large enough to scale up coverage to 75% 
of the HIV-seropositive population to have a significant impact on tuberculosis and HIV-associated deaths. 
Incremental scale-up at low levels of coverage will have limited success in averting deaths. For HIV-associated
!

tuberculosis deaths, provision of HAART alone is likely to be more effective public health strategy than provision of
effective MDRTB treatment alone.
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Table 1: Initial conditions for the simulation model reflecting estimated situation in Samara Oblast (January 
2003)
Stock (Variable State) Initial value in the Simulation Model
Susceptible TB –HIV (seronegative) 1,608,596
Susceptible TB –HIV (seropositive) 12,044
Latently Infected DSTB –HIV (seronegative) 681,408
Latently Infected DSTB –HIV (seropositive) 4,862
Disease DSTB –HIV (seronegative) 1400
Disease DSTB –HIV (seropositive) 100
Disease MDRTB –HIV (seronegative) 1,146
Disease MDRTB –HIV (seropositive) 44
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Figure 2: The HIV/AIDS transmission sub-system for the tuberculosis state ‘Latently Infected DSTB’










Death Rate without HAART
Death Rate with HAART
Figure 3: Cumulative deaths at 10 years from tuberculosis at varying HAART coverage levels and MDRTB 
























MDRTB Cure Rate 5% MDRTB Cure Rate 80%
Figure 4: Cumulative HIV-associated tuberculosis deaths at 10 years at varying HAART coverage levels and 
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